MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 531438 | Name: ALX-1393

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ALX 1393 is a glycine transporter-2 (GlyT2) inhibitor. ALX 1393 inhibits spontaneous network activity by inducing glycinergic tonic currents in the spinal ventral horn. GlyT2 inhibition by ALX 1393 potently reduced neuronal action potential activity in a concentration-dependent manner (n=211). The half maximal effect of ALX 1393 was observed at 100 ± 31 nM. Moreover, 88.3 ± 2.6% of the action potential activity was suppressed at 1 μM.

Chemical Structure

ALX-1393
ALX-1393
CAS#949164-09-4

Theoretical Analysis

MedKoo Cat#: 531438

Name: ALX-1393

CAS#: 949164-09-4

Chemical Formula: C23H22FNO4

Exact Mass: 395.1533

Molecular Weight: 395.43

Elemental Analysis: C, 69.86; H, 5.61; F, 4.80; N, 3.54; O, 16.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ALX1393; ALX-1393; ALX 1393;
IUPAC/Chemical Name
(2S)-2-amino-3-{[2-(benzyloxy)phenyl](3-fluorophenyl)methoxy}propanoic acid
InChi Key
ADUSZEGHFWRTQS-AIBWNMTMSA-N
InChi Code
InChI=1S/C23H22FNO4/c24-18-10-6-9-17(13-18)22(29-15-20(25)23(26)27)19-11-4-5-12-21(19)28-14-16-7-2-1-3-8-16/h1-13,20,22H,14-15,25H2,(H,26,27)/t20-,22?/m0/s1
SMILES Code
O=C(O)[C@@H](N)COC(C1=CC=CC=C1OCC2=CC=CC=C2)C3=CC=CC(F)=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Strychnine-sensitive glycine receptors are activated by glycine and facilitate chloride influx into neurons. Glycinergic transmission might be either mediated by synaptic or extrasynaptic glycine receptors. While phasic neurotransmission is provided by a synaptic pathway, activation of extrasynaptic glycine receptors induces tonic inhibition. The glycine transporter 2 (GlyT2) regulates the uptake of glycine into presynaptic boutons.
Solvent mg/mL mM comments
Solubility
TBD 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 395.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Benito-Muñoz C, Perona A, Felipe R, Pérez-Siles G, Núñez E, Aragón C, López- Corcuera B. Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543. ACS Chem Neurosci. 2021 Jun 2;12(11):1860-1872. doi: 10.1021/acschemneuro.0c00602. Epub 2021 May 18. PMID: 34003005; PMCID: PMC8691691. 2: Al-Khrasani M, Mohammadzadeh A, Balogh M, Király K, Barsi S, Hajnal B, Köles L, Zádori ZS, Harsing LG Jr. Glycine transporter inhibitors: A new avenue for managing neuropathic pain. Brain Res Bull. 2019 Oct;152:143-158. doi: 10.1016/j.brainresbull.2019.07.008. Epub 2019 Jul 11. PMID: 31302238. 3: Kamizato K, Marsala S, Navarro M, Kakinohana M, Platoshyn O, Yoshizumi T, Lukacova N, Wancewicz E, Powers B, Mazur C, Marsala M. Time-dependent, bidirectional, anti- and pro-spinal hyper-reflexia and muscle spasticity effect after chronic spinal glycine transporter 2 (GlyT2) oligonucleotide-induced downregulation. Exp Neurol. 2018 Jul;305:66-75. doi: 10.1016/j.expneurol.2018.03.013. Epub 2018 Mar 30. PMID: 29608917. 4: Yang J, Han F, Liu W, Chen H, Hao X, Jiang X, Yin L, Huang Y, Cao J, Zhang H, Liu J. ALX4, an epigenetically down regulated tumor suppressor, inhibits breast cancer progression by interfering Wnt/β-catenin pathway. J Exp Clin Cancer Res. 2017 Nov 28;36(1):170. doi: 10.1186/s13046-017-0643-9. PMID: 29183346; PMCID: PMC5706407. 5: Oyama M, Kuraoka S, Watanabe S, Iwai T, Tanabe M. Electrophysiological evidence of increased glycine receptor-mediated phasic and tonic inhibition by blockade of glycine transporters in spinal superficial dorsal horn neurons of adult mice. J Pharmacol Sci. 2017 Mar;133(3):162-167. doi: 10.1016/j.jphs.2017.02.011. Epub 2017 Feb 27. PMID: 28302446. 6: Takahashi Y, Hara K, Haranishi Y, Terada T, Obara G, Sata T. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. Pharmacol Biochem Behav. 2015 Mar;130:46-52. doi: 10.1016/j.pbb.2015.01.001. Epub 2015 Jan 9. PMID: 25579325. 7: Motoyama N, Morita K, Shiraishi S, Kitayama T, Kanematsu T, Uezono Y, Dohi T. Relief of cancer pain by glycine transporter inhibitors. Anesth Analg. 2014 Oct;119(4):988-995. doi: 10.1213/ANE.0000000000000388. PMID: 25076101. 8: Barthel F, Urban A, Schlösser L, Eulenburg V, Werdehausen R, Brandenburger T, Aragon C, Bauer I, Hermanns H. Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats. Anesthesiology. 2014 Jul;121(1):160-9. doi: 10.1097/ALN.0000000000000203. PMID: 24598217. 9: Eckle VS, Antkowiak B. ALX 1393 inhibits spontaneous network activity by inducing glycinergic tonic currents in the spinal ventral horn. Neuroscience. 2013 Dec 3;253:165-71. doi: 10.1016/j.neuroscience.2013.08.042. Epub 2013 Aug 29. PMID: 23994185. 10: Mingorance-Le Meur A, Ghisdal P, Mullier B, De Ron P, Downey P, Van Der Perren C, Declercq V, Cornelis S, Famelart M, Van Asperen J, Jnoff E, Courade JP. Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain. Br J Pharmacol. 2013 Nov;170(5):1053-63. doi: 10.1111/bph.12343. PMID: 23962079; PMCID: PMC3949653. 11: Yoshikawa S, Oguchi T, Funahashi Y, de Groat WC, Yoshimura N. Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats. Eur Urol. 2012 Oct;62(4):704-12. doi: 10.1016/j.eururo.2012.01.044. Epub 2012 Feb 1. PMID: 22341128; PMCID: PMC3414688. 12: Nimmervoll B, Denter DG, Sava I, Kilb W, Luhmann HJ. Glycine receptors influence radial migration in the embryonic mouse neocortex. Neuroreport. 2011 Jul 13;22(10):509-13. doi: 10.1097/WNR.0b013e328348aafe. PMID: 21666516. 13: Jeong HJ, Vandenberg RJ, Vaughan CW. N-arachidonyl-glycine modulates synaptic transmission in superficial dorsal horn. Br J Pharmacol. 2010 Oct;161(4):925-35. doi: 10.1111/j.1476-5381.2010.00935.x. PMID: 20860669; PMCID: PMC2992905. 14: Nishikawa Y, Sasaki A, Kuraishi Y. Blockade of glycine transporter (GlyT) 2, but not GlyT1, ameliorates dynamic and static mechanical allodynia in mice with herpetic or postherpetic pain. J Pharmacol Sci. 2010;112(3):352-60. doi: 10.1254/jphs.09351fp. Epub 2010 Feb 20. PMID: 20173309. 15: Haranishi Y, Hara K, Terada T, Nakamura S, Sata T. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. Anesth Analg. 2010 Feb 1;110(2):615-21. doi: 10.1213/ANE.0b013e3181c7ebbb. PMID: 20081141. 16: Hermanns H, Muth-Selbach U, Williams R, Krug S, Lipfert P, Werdehausen R, Braun S, Bauer I. Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain. Neurosci Lett. 2008 Nov 21;445(3):214-9. doi: 10.1016/j.neulet.2008.09.012. Epub 2008 Sep 11. PMID: 18793697. 17: Micu I, Ridsdale A, Zhang L, Woulfe J, McClintock J, Brantner CA, Andrews SB, Stys PK. Real-time measurement of free Ca2+ changes in CNS myelin by two- photon microscopy. Nat Med. 2007 Jul;13(7):874-9. doi: 10.1038/nm1568. Epub 2007 Jul 1. PMID: 17603496. 18: Xu TX, Gong N, Xu TL. Inhibitors of GlyT1 and GlyT2 differentially modulate inhibitory transmission. Neuroreport. 2005 Aug 1;16(11):1227-31. doi: 10.1097/00001756-200508010-00019. PMID: 16012354.